药品批准更新
Pharmaceutical Approval Update.
作者信息
Kaufman Michele B
出版信息
P T. 2017 Sep;42(9):562-580.
Abstract
Sarilumab (Kevzara) for moderately to severely active rheumatoid arthritis; valbenazine (Ingrezza), the first approval for tardive dyskinesia; and cerliponase alpha (Brineura) for late infantile neuronal ceroid lipofuscinosis type-2 disease.
摘要
用于中度至重度活动性类风湿关节炎的托珠单抗（凯纷）；用于迟发性运动障碍的首个获批药物瓦尔贝扎嗪（因格雷扎）；以及用于2型晚发性婴儿神经元蜡样脂褐质沉积症的赛立普酶α（布瑞诺龙）。
相似文献
1
Pharmaceutical Approval Update.药品批准更新
P T. 2017 Sep;42(9):562-580.
2
Cerliponase alfa for neuronal ceroid lipofuscinosis type 2 disease.阿法西瑞酶用于治疗2型神经元蜡样脂褐质沉积症。
Aust Prescr. 2019 Jun;42(3):102. doi: 10.18773/austprescr.2019.029. Epub 2019 Apr 24.
3
4
Changing Times for CLN2 Disease: The Era of Enzyme Replacement Therapy.CLN2病的时代变迁：酶替代疗法时代
Ther Clin Risk Manag. 2020 Mar 30;16:213-222. doi: 10.2147/TCRM.S241048. eCollection 2020.
5
Valbenazine granted breakthrough drug status for treating tardive dyskinesia.氘代丁苯那嗪获批用于治疗迟发性运动障碍的突破性药物地位。
Expert Opin Investig Drugs. 2015 Jun;24(6):737-42. doi: 10.1517/13543784.2015.1029573. Epub 2015 Mar 25.
6
Valbenazine for the treatment of tardive dyskinesia.用于治疗迟发性运动障碍的氘代丁苯那嗪
Drugs Today (Barc). 2016 Dec;52(12):665-672. doi: 10.1358/dot.2016.52.12.2570977.
7
Cerliponase Alfa: First Global Approval.西利鲁单抗：全球首次获批。
Drugs. 2017 Jul;77(11):1247-1249. doi: 10.1007/s40265-017-0771-8.
8
Sarilumab: A Review in Moderate to Severe Rheumatoid Arthritis.沙利鲁单抗：治疗中重度类风湿关节炎的研究进展。
Drugs. 2018 Jun;78(9):929-940. doi: 10.1007/s40265-018-0929-z.
9
The neuronal ceroid-lipofuscinoses.神经元蜡样脂褐质沉积症
J Child Neurol. 1995 Nov;10(6):424-37. doi: 10.1177/088307389501000602.
10
Valbenazine for Tardive Dyskinesia.用于迟发性运动障碍的氘代丁苯那嗪
Clin Schizophr Relat Psychoses. 2017 Summer;11(2):113-119. doi: 10.3371/CSRP.OFGR.071717.
引用本文的文献
1
Plausible mechanism of drug resistance and side-effects of COVID-19 therapeutics: a bottleneck for its eradication.新冠病毒治疗药物耐药性和副作用的可能机制：其根除的瓶颈。
Daru. 2024 Dec;32(2):801-823. doi: 10.1007/s40199-024-00524-z. Epub 2024 Jul 19.
2
Meeting the Therapeutic Challenges of Emergent and Rare Invasive Fungal Diseases Through Novel Clinical Trial Designs.通过新型临床试验设计应对紧急和罕见侵袭性真菌病的治疗挑战。
Open Forum Infect Dis. 2024 Jun 17;11(6):ofae257. doi: 10.1093/ofid/ofae257. eCollection 2024 Jun.
3
Combating the challenges of COVID-19 pandemic: Insights into molecular mechanisms, immune responses and therapeutics against SARS-CoV-2.应对新冠疫情的挑战：对针对严重急性呼吸综合征冠状病毒2的分子机制、免疫反应及治疗方法的见解
Oxf Open Immunol. 2023 Jan 10;4(1):iqad001. doi: 10.1093/oxfimm/iqad001. eCollection 2023.
4
Carbohydrate-Small Molecule Hybrids as Lead Compounds Targeting IL-6 Signaling.碳水化合物-小分子杂合体作为靶向 IL-6 信号的先导化合物。
Molecules. 2023 Jan 9;28(2):677. doi: 10.3390/molecules28020677.
5
[Neuroinflammation in neuronal ceroid lipofuscinosis].[神经元蜡样脂褐质沉积症中的神经炎症]
Ophthalmologe. 2021 Feb;118(2):98-105. doi: 10.1007/s00347-020-01301-4. Epub 2021 Jan 7.
6
Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches.中枢神经系统疾病的被动免疫疗法：当前的传递挑战和新方法。
Bioconjug Chem. 2018 Dec 19;29(12):3937-3966. doi: 10.1021/acs.bioconjchem.8b00548. Epub 2018 Oct 24.
Zotero 插件